{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:55:02Z","timestamp":1793152502486,"version":"4.5.0"},"reference-count":43,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2022,5,1]]},"DOI":"10.1001\/jamainternmed.2022.0338","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T11:34:07Z","timestamp":1648467247000},"page":"513","source":"Crossref","is-referenced-by-count":361,"title":["Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases"],"prefix":"10.1001","volume":"182","author":[{"given":"Liyun","family":"He","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology of the National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology of the National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Ping","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology of the National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology of the National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyue","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology of the National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology of the National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology of the National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology of the National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huabing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology of the National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"13","key":"ioi220009r1","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1056\/NEJMcp2000280","article-title":"Glucose-lowering drugs to reduce cardiovascular risk in type 2 diabetes.","volume":"384","author":"Kalyani","year":"2021","journal-title":"N Engl J Med"},{"issue":"17","key":"ioi220009r2","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1093\/eurheartj\/ehab175","article-title":"GLP-1 receptor agonists: fighting obesity with an eye to cardiovascular risk.","volume":"42","author":"Liuzzo","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"ioi220009r3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S2213-8587(20)30343-0","article-title":"Guideline recommendations and the positioning of newer drugs in type 2 diabetes care.","volume":"9","author":"Marx","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"ioi220009r4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/eurheartj\/ehz853","article-title":"Compelling evidence for SGLT2 inhibitors and GLP-1 receptor agonists as first-line therapy in patients with diabetes at very high\/high cardiovascular risk.","volume":"41","author":"Marx","year":"2020","journal-title":"Eur Heart J"},{"issue":"14","key":"ioi220009r5","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial.","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"issue":"11","key":"ioi220009r6","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once weekly semaglutide in adults with overweight or obesity.","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"18","key":"ioi220009r7","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","article-title":"Healthy weight loss maintenance with exercise, liraglutide, or both combined.","volume":"384","author":"Lundgren","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"ioi220009r8","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.2337\/dc19-0415","article-title":"Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial.","volume":"42","author":"Nauck","year":"2019","journal-title":"Diabetes Care"},{"issue":"8","key":"ioi220009r9","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40264-019-00812-7","article-title":"Benefit-risk assessment of obesity drugs: focus on glucagon-like peptide-1 receptor agonists.","volume":"42","author":"Christensen","year":"2019","journal-title":"Drug Saf"},{"issue":"4","key":"ioi220009r12","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Intern Med"},{"key":"ioi220009r13","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"1537","key":"ioi220009r15","doi-asserted-by":"publisher","first-page":"n1537","DOI":"10.1136\/bmj.n1537","article-title":"Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses.","volume":"374","author":"Cai","year":"2021","journal-title":"BMJ"},{"key":"ioi220009r16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jclinepi.2019.03.007","article-title":"The number needed to treat in pairwise and network meta-analysis and its graphical representation.","volume":"111","author":"Veroniki","year":"2019","journal-title":"J Clin Epidemiol"},{"issue":"7650","key":"ioi220009r17","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"9","key":"ioi220009r18","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1111\/dom.2017.19.issue-9","article-title":"Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.","volume":"19","author":"Monami","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"ioi220009r19","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108087","article-title":"Cholelithiasis in patients treated with glucagon-like peptide-1 receptor: an updated meta-analysis of randomized controlled trials.","volume":"161","author":"Nreu","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"issue":"10278","key":"ioi220009r20","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"ioi220009r21","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1002\/jcph.v57.10","article-title":"Effect of albiglutide on cholecystokinin-induced gallbladder emptying in healthy individuals: a randomized crossover study.","volume":"57","author":"Shaddinger","year":"2017","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"ioi220009r22","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1080\/00365521.2018.1530297","article-title":"Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs.","volume":"53","author":"Rehfeld","year":"2018","journal-title":"Scand J Gastroenterol"},{"issue":"11","key":"ioi220009r23","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1111\/dom.2018.20.issue-11","article-title":"Effects of liraglutide on gallbladder emptying: A randomized, placebo-controlled trial in adults with overweight or obesity.","volume":"20","author":"Nex\u00f8e-Larsen","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"ioi220009r24","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1210\/jc.2018-01008","article-title":"New Avenues in the regulation of gallbladder motility-implications for the use of glucagon-like peptide-derived drugs.","volume":"104","author":"Gether","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"ioi220009r25","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1001\/jamainternmed.2016.1531","article-title":"Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus.","volume":"176","author":"Faillie","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"18","key":"ioi220009r26","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","article-title":"Healthy weight loss maintenance with exercise, liraglutide, or both combined.","volume":"384","author":"Lundgren","year":"2021","journal-title":"N Engl J Med"},{"issue":"18","key":"ioi220009r27","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1056\/NEJMc1611289","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes.","volume":"375","author":"\u00c1lvarez-Villalobos","year":"2016","journal-title":"N Engl J Med"},{"issue":"13","key":"ioi220009r28","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once weekly exenatide on cardiovascular outcomes in type 2 diabetes.","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"ioi220009r30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s13679-020-00422-w","article-title":"Long-term efficacy and safety of anti-obesity treatment: where do we stand?","volume":"10","author":"Tak","year":"2021","journal-title":"Curr Obes Rep"},{"key":"ioi220009r37","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.645617","article-title":"Efficacy of semaglutide in a subcutaneous and an oral formulation.","volume":"12","author":"Meier","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"15","key":"ioi220009r38","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2017.14752","article-title":"Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial.","volume":"318","author":"Davies","year":"2017","journal-title":"JAMA"},{"key":"ioi220009r39","doi-asserted-by":"publisher","first-page":"S334","DOI":"10.1007\/s00125-012-2688-9","article-title":"Efficacy and safety of lixisenatide once daily versus placebo in patients with type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P).","volume":"55","author":"Pinget","year":"2012","journal-title":"Diabetologia"},{"key":"ioi220009r40","doi-asserted-by":"publisher","first-page":"S317","DOI":"10.1007\/s00125-011-2276-4","article-title":"Efficacy and safety of lixisenatide once daily versus placebo in patients with type 2 diabetes mellitus insufficiently controlled on sulfonylurea \u00b1 metformin (GetGoal-S).","volume":"54","author":"Ratner","year":"2011","journal-title":"Diabetologia"},{"key":"ioi220009r41","doi-asserted-by":"publisher","first-page":"S359","DOI":"10.1007\/s00125-013-3012-z","article-title":"HARMONY 1 results at week 52 primary endpoint: once weekly albiglutide vs placebo in patients with type 2 diabetes mellitus not controlled on pioglitazone \u00b1 metformin.","volume":"56","author":"Reusch","year":"2013","journal-title":"Diabetologia"},{"key":"ioi220009r42","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ahj.2018.03.030","article-title":"Harmony outcomes: a randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus: rationale, design, and baseline characteristics.","volume":"203","author":"Green","year":"2018","journal-title":"Am Heart J"},{"issue":"9","key":"ioi220009r43","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S2213-8587(21)00174-1","article-title":"Efficacy and safety of once weekly semaglutide 2\u00b70 mg versus 1\u00b70 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial.","volume":"9","author":"Fr\u00edas","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ioi220009r10","unstructured":"US Food and Drug Administration. Drugs@FDA: FDA approved drug products. Accessed February 22, 2022. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm"},{"key":"ioi220009r11","unstructured":"European Medicines Agency. Medicines. Accessed February 22, 2022. https:\/\/www.ema.europa.eu\/en\/medicines"},{"key":"ioi220009r14","unstructured":"Higgins? JPT, Thomas? J, Chandler? J, , eds. Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Accessed February 22, 2022. www.training.cochrane.org\/handbook."},{"key":"ioi220009r29","unstructured":"US Food and Drug Administration. FDA approves new drug treatment for chronic weight management, first since 2014. Accessed February 23, 2022. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-drug-treatment-chronic-weight-management-first-2014"},{"key":"ioi220009r31","unstructured":"European Medicines Agency. Trulicity. Accessed February 23, 2022. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/trulicity"},{"key":"ioi220009r32","unstructured":"US Food and Drug Administration. Drug approval package Trulicity (dulaglutide) injection. NDA No. 125469. Accessed February 23, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/125469Orig1s000TOC.cfm"},{"key":"ioi220009r33","unstructured":"AstraZeneca. Bydureon BCise full prescribing information. Accessed February 23, 2022. http:\/\/www.azpicentral.com\/pi.html?product=bydureon_bcise"},{"key":"ioi220009r34","unstructured":"European Medicines Agency. Bydureon, annex I: summary of product characteristics. Accessed February 23, 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bydureon-epar-product-information_en.pdf"},{"key":"ioi220009r35","unstructured":"US Food and Drug Administration. Ozempic. NDA No. 209637. Accessed February 23, 2022. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&varApplNo=209637"},{"key":"ioi220009r36","unstructured":"European Medicines Agency. Ozempic: EPAR product information. Accessed February 23, 2022. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ozempic#product-information-section"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2790392\/jamainternal_he_2022_oi_220009_1650900276.01193.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T11:02:55Z","timestamp":1651489375000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2790392"}},"subtitle":["A Systematic Review and Meta-analysis of Randomized Clinical Trials"],"short-title":[],"issued":{"date-parts":[[2022,5,1]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2022.0338","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,1]]}}}